Close

News

RNA-based therapy brings new hope for an incurable blood cancer

Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma...

Rare disease researchers notch a win for patients with inherited muscle disease

An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Journal...

Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement

Sanofi and Bristol-Myers Squibb Company have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets. Under the terms of the revised agreement, which will go...

New antibiotic cures disease by disarming pathogens

A new type of antibiotic can effectively treat an antibiotic-resistant infection by disarming instead of killing the bacteria that cause it. Researchers report their findings in the October 2 issue of mBio®, the online open-access journal of the...

Biological markers increase clinical trial success rate of new breast cancer drugs

Using biological markers - genetic characteristics that are associated with some patients with breast cancer - can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the...

Bayer’s Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer

Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and...

Roche leads healthcare sector in key sustainability index for fourth consecutive year

Roche  has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and DJSI Europe Indexes track the performance of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »